Goals of Planned National Pain Research Consortium Outlined

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

WASHINGTON--An announcement by NIH director Harold E. Varmus, MD, of a plan to form a national pain research consortium came as a complete, but pleasant surprise to the American Pain Society, Martin Grabois, MD, president of the Society, said in an interview with Oncology News International.

WASHINGTON--An announcement by NIH director Harold E. Varmus, MD, ofa plan to form a national pain research consortium came as a complete,but pleasant surprise to the American Pain Society, Martin Grabois, MD,president of the Society, said in an interview with Oncology News International.

In his keynote address at the Society's Annual Scientific Meeting, Dr.Varmus said that the consortium will comprise representatives from variousbranches of the NIH, including, but not limited to, the National Instituteof Neurological Diseases and Stroke, National Cancer Institute, NationalInstitute on Aging, and National Institute of Arthritis and Musculoskeletaland Skin Diseases.

Dr. Varmus said that the consortium would serve as a centralized clearinghousefor projects and information on pain, help to publicize the aims and accomplishmentsof pain specialists, and foster collaboration and dialogue among scientists,pain societies, advocacy groups, and other members of the pain community.

Proposed Functions of the Planned NIH Pain Research Consortium

Dr. Grabois, professor and chairman of physical medicine and rehabilitation,Baylor College of Medicine, said that the Society was very enthused bythe announcement. If the consortium carries out the goals and functionsDr. Varmus described in his talk (see table above), he said, "I thinkthat would go a long way toward upgrading pain research conducted at NIHor with NIH support." However, he noted that Dr. Varmus included notime frame for the formation of the consortium. "We would like tosee how the plan is implemented and take a look a year later to see howwell the consortium's stated goals have been met."

Charles S. Cleeland, PhD, outgoing president of the Society, said thatthe consortium would bring a "needed level of coordination of painresearch at the NIH." He added that he hoped the consortium "willlook for advice and counsel from the community of patients who suffer painand the professionals who try to help these patients."

Recent Videos
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
Related Content